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A group of interesting molecules called defensins exhibit multiple functions but have been primarily recognized to possess a broad spectrum of
antimicrobial activities. Studies have reported two different types of defensins (α and β) from human and animals, a cyclic θ defensin from rhesus,
and several defensin-like peptides from plants. There is no amino acid sequence homology between these peptides, but they all contain three Cys–
Cys disulfide linkages while the connectivities are different. Human β-defensin-3 (HβD-3) is the most recently discovered member of the host-
defense peptide family that has attracted much attention. This molecule is expressed either constitutively or induced upon a challenge, and a
growing evidence indicates the involvement of such molecules in adaptive immunity as well. It has been shown to exhibit antibacterial activities
towards Gram-negative and Gram-positive bacteria as well as an ability to act as a chemo-attractant. Analysis of NMR structural data suggested a
symmetrical dimeric form of this peptide in solution, which consists of three β strands and a short helix in the N-terminal region. While the
disulfide linkages are known to provide the structural stability and stability against proteases, the biological relevance of this dimeric form was
contradicted by another biological study. Since there is considerable current interest in developing HβD-3 for possible pharmaceutical
applications, studies to further our understanding on the determinants of antibacterial activities and immunomodulatory function of HβD-3 are
considered to be highly significant. The knowledge of its biosynthetic regulation will also help in understanding the role of HβD-3 in immunity.
This article presents an overview of the expression and regulation of HβD-3 in humans, and the structure–function correlations among HβD-3 and
its modified peptides are discussed emphasizing the functional importance. The future scope for studies on HβD-3 and design of short potent
antimicrobial peptides, based on the native HβD-3 molecule, that do not interfere in the immunomodulatory function is also outlined.
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Defensins are a family of antimicrobial peptides and vital
contributors to host immune response. Being constitutively or
inducibly expressed, they have been shown to contribute to
innate host defense via direct bacteriocidal activity, as well as to
adaptive immunity through effector and regulatory functions.
Defensins are an efficient part of the first line of host defense
because of their ability to recognize and neutralize invading
microorganisms quickly and specifically. Defensins show
antimicrobial activities against Gram-negative and Gram-
positive bacterial strains and fungi, as well as some parasites
and enveloped viruses. Their mechanism of activity is known to
involve membrane permeabilization, although different pep-
tides act in different ways and exact mechanisms are only
beginning to be elucidated [1–3]. This relatively non-specific
membrane permeating mechanism makes incidence of resistant
bacteria rare. Defensins also exhibit chemotactic behavior for
certain cells and function to induce the adaptive immune
system. Certain defensins play different roles in recruitment and
exhibit receptor-specific chemotactic activity. Overall, defen-
sins have a great potential for pharmaceutical applications as
antibiotics as well as modulators of inflammation [1]. As a
family, the defensins deserve a special attention due to their
particular prominence in humans, constituting a number of
genes and being extensively present in human tissues.
While there are three distinct classes of defensins (α, β, and
θ-defensins), only α- and β-defensins are expressed in humans
(for a regularly updated list of plant and animal antimicrobial
peptides, see the website: http://www.bbcm.univ.trieste.it/
~tossi/antimic.html, and also references [4] and [5]). Both α-
and β-defensins are short cationic peptides (29–45 residues)
containing six conserved cysteine residues involved in disulfide
linkages. The tertiary structure of these peptides consists of
three antiparallel β-sheets, which are constrained by cysteine
residues, making up the characteristic “defensin-like” fold and
spatially separated hydrophobic and hydrophilic regions. α- and
β-defensins are products of distinct gene families that are
thought to have evolved from an ancestral β-defensin gene; α-
defensins show an evidence of being newer because they are
more homologous as a group and exist only in mammals. This
divergence resulted in adjacent clusters on chromosomal maps
for α- and β-defensin genes; in humans on chromosome 8p23,
although some newly identified β-defensin genes map to
different chromosomes [6,7].
The disulfide connectivities in α-defensins are Cys1–Cys6,
Cys2–Cys4 and Cys3–Cys5 (the number indicates the location
of the Cys residue in the amino acid sequence from the N-
terminus). They are expressed in human neutrophil cells, Paneth
cells of the small intestine, and a very few epithelial cells. The
four human α-defensins originally isolated from neutrophil cells
are named as HNP1–4 (human neutrophil peptides); HD-5 and
HD-6 (where HD stands for the human defensin) are products of
Paneth cells.
The disulfide connectivities in β-defensin are Cys1–Cys5,
Cys2–Cys4 and Cys3–Cys6. β-defensins are found in epithelial
cells. Human β-defensins are named as HβD-1–4 and wereoriginally isolated from human plasma (HβD-1) and psoriatic
scales (HβD-2, HβD-3); HβD-4 has not yet been isolated, but
identified solely by genomics. The human genome suggests that
there are at least 25 β-defensins that are yet to be discovered [8].
HβD-1 is constitutively expressed in some tissues (but can also
be upregulated), while HβD-2–4 are inducible, usually in
response to pro-inflammatory stimuli. β-defensins have been
shown to be ligands for chemokine receptor CCR6 on dendritic
cells (DCs) and T cells; this is the basis of their activity as
effector molecules of adaptive immunity.
Studies continue to show specific activities of certain
defensins and their activity against specific microbial agents.
Difficulties arise in correlating in vitro and in vivo activities of
defensins, as well as differentiating the activities of antimicro-
bial peptides from that of other components of the immune
system due to their overlap in function. Another problem is that
the in vitro antimicrobial activities of most defensins are dulled
by physiological salts, divalent cations and serum proteins; the
magnitude of inhibition depends on the defensin and its target
bacteria. These sensitivities suggest that most of the defensin
activities take place in membrane sequestered environments
where salt and serum concentrations are low and defensin
concentrations are high, such as phagocytic vacuoles or the
external surface of skin and mucus membranes.
2. β-Defensins and their roles in diseases
As defensins are a part of the host immune system, they are
implicated in a wide variety of conditions and diseases. In many
cases, a disease state is accompanied by a change in the amount
of defensin expression in the diseased tissue. Patients with
vascular diseases have shown high levels of defensins in
atherosclerotic plaques in humans. In this way, defensins may
be mediators of vascular diseases. It was found that defensins
interfere with LDL (low density lipoprotein, known as “bad
cholesterol”) and Lp(a) (lipoprotein a) degradation and there-
fore contribute to the accumulation of these lipoproteins.
Defensins also appear to inhibit angiogenesis, a defect
associated with traumatic aortic dissection and coronary artery
disease [9].
Crohn's disease is an inflammatory disease of the intestinal
tract that until recently had no identifiable cause. It has recently
been shown that the relationship between the host and
commensal gastrointestinal bacteria in Crohn's patients has
been disturbed. In healthy patients, defensins help keep up the
beneficial relationship with these commensal bacteria; distur-
bance of defensin levels can therefore cause commensal bacteria
to become pathogenic, leading to gastrointestinal infections and
disease [10]. Defensin levels have also been shown to be low in
patients suffering from irritable bowel syndrome [11].
In bronchoalveolar inflammation and skin diseases (such as
psoriasis and mastitis) expression and peptide concentrations of
HβD-2 and HβD-3 are increased; as a result of these high
defensin levels psoriatic lesions rarely become infected [3,12].
In contrast, the skin condition atopic dermatitis shows decreased
HβD-2 and HβD-3 levels; this condition is often accompanied
by bacterial, fungal, or viral infection [3].
Table 1
Expression of HβD-3 in different parts of the human body
Site of expression Reference
Skin, trachea, tongue, uterus, pharynx, kidney, thymus,
colon, stomach, adenoid
[25]
Placenta [42]
Endometrium [41]
Non-inflamed oral tissue samples:
Gingiva, tongue, buccal mucosa, labial mucosa,
floor of the mouth—mucosa, dental follicle
[34]
Inflamed oral tissue samples:
Gingivitis, marginal periodontitis, apical periodontitis,
candidiasis
[34]
In salivary glands:
Submandibular gland, small labial gland [34]
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mutations in the CF transmembrane regulator gene, which
encodes regulated chloride ion channels. The main cause of
death in patients with CF is respiratory failure, perhaps due to
progressive damage to lungs and airways due to recurring
infections and inflammation. Infection with Pseudomonas
aeruginosa marks the onset of progressive lung disease. The
infections are almost always localized only in the lung,
indicating a defect in local epithelial host defense. It has
therefore been suggested that this defect is caused by the
inhibition of defensin activity, which is due to the abnormal
ionic state of CF airway fluid. A normal fluid is low in salt,
which favors the activity of defensins, but CF fluid has been
reported to be very high in salt due to lack of the function of
CFTR protein that forms chloride ion channels. This high salt
environment may inhibit defensin activity and compromise host
respiratory defense [6]. On the other hand, the pro-inflamma-
tory activity of antimicrobial peptides is likely to have negative
consequences. For example, in CF patients, lung washings have
cytotoxic levels of α-defensins [1].
Among the identified human β-defensins, HβD-3 is of
special interest for structural and functional studies and also for
possible pharmaceutical applications. It is also one among the
identified human defensins that has the ability to undergo
oligomerization [13–15]. Its ability to exhibit antibacterial
activity at physiological salt concentrations towards Gram-
positive bacteria and its involvement in adaptive immunity are
of biological significance as compared to other human
defensins. The ability to form a dimer that leads to the
formation of higher ordered oligomeric structures is possibly
responsible for unique characteristics of HβD-3. These proper-
ties of HβD-3 are of current interest and warrant further studies,
though a modified analog of HβD-3 has been shown to form
only monomeric structures and retain antibacterial activity [16].
It is therefore expected that future studies on this peptide will be
directed towards understanding the discrete structural elements
that may be responsible for its biological activity and the steps
involved in the functional regulation of HβD-3.
3. Expression and regulation of HβD-3
The molecular evolution of gene coding for β-defensin 3
deduced 17 amino acid sequences in primates including human
[16]. The primates analyzed were from Great Apes, Hylobati-
dae, Cercopithecidae, and Platyrrhine species. The alignment of
nucleotide sequences from the coding region of the β-defensin 3
gene showed a greater identity implying conservation and
evolutionary significance [16,17].
In humans, β-defensins are found mainly at epithelial
surfaces, for example in gut and lung [18,19]. It has been
reported that there are 28 defensin-like sequences in the human
genome [20] but currently only HβD-1–6 have been character-
ized as part of the β-defensin family [21–26]. The β-defensins
are further subdivided on the basis of their expression: those that
are constitutively expressed (e.g. HβD-1) and those that are
induced upon challenge with inflammatory or pathogen-derived
stimuli [24,25,27–29]. In addition to their role as antimicro-bials, β-defensins are chemoattractants promoting interactions
between innate and acquired immune systems [23,24,30].
HβD-3 was first isolated from human lesional psoriatic
scales. It has also been isolated from primary keratinocytes and
lung epithelial cells pretreated with P. aeruginosa [25]. Table 1
shows some of the reports on the expression of HβD-3 in
different tissues of the human system. Recently, the presence of
HβD-3 peptide has been confirmed in homogenates of human
lung, serum and gingival epithelia using RP-HPLC, radio-
immunoassay, immunohistochemistry and in situ hybridization
indicating the pathophysiological significance of this molecule
in respiratory infections and in maintenance of periodontal
homeostasis [31,32]. The expression of HβD-3 in engineered
epidermis shown to provide protection against bacterial
infection and thereby indicating potential therapeutic applica-
tions of this molecule by gene therapy to combat infectious
diseases [33].
Analysis of HβD-3 gene expression in various body organs
by real-time reverse-transcription polymerase chain reaction
(RT-PCR) indicated strong expression of HβD-3 mRNA in
skin, trachea, tongue and tonsils, whereas lower levels of
expression were shown in organs like salivary glands, uterus,
kidney, bone marrow, thymus, colon, stomach, adenoid,
pharynx, and larynx. The RT-PCR also detected expression of
HβD-3 in both inflamed and non-inflamed oral tissues and in
salivary glands [34]. The HβD-3 expression is inducible on
ocular surface epithelial cells and was observed to a greater
extent in corneal and conjunctival infected samples than that of
the noninfected samples [35]. A modified quantitative RT-PCR
method is a fast and reliable tool for the screening of copy
numbers of polymorphisms in β-defensin genes and is also
useful for expression and epidemiologic studies [36].
The expression, regulation, and roles of β-defensins at non-
reproductive sites have been reviewed in detail [37–39]. In
human endometrial epithelium, the expression profiles of each
of the beta-defensins (defensins 1–4) are related to the stage of
the menstrual cycle. HβD-3 has been shown to express at the
highest level compared to other defensins during early and late
secretory phases [40,41].
The expression of HβD-3 has been found to be induced by
external stimuli including interleukin-1, tumor necrosis factor-
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bacteria [23,25,42,43]. cDNA isolation from primary keratino-
cytes encoded a 67-residue precursor preprotein that is
processed by proteolytic activation to a mature 45-residues
peptide having structural similarity to vertebrate epithelial
defensins. A 3–8 fold increase in mRNA levels of HβD-3 was
observed when normal human oral epithelial cells were
challenged with C. albicans, while challenging with HIV-1
strains of X4 and R5 viral bio-phenotypes resulted in a 78 fold
increase in mRNA levels of HβD-3 [44–46]. The induced
expression of HβD-3 in keratinocytes by microbial stimuli was
found to be mediated by transactivation of epidermal growth
factor receptor (EFGR), which is distinct and also suggests
differential regulation of expression among human β-defensins
1, 2 and 3 [47].
Jia et al. used a genomics based approach to identify the
HβD-3 genes [42]. The human defensin genes are clustered to a
<8Mb region of the chromosome 8p22–p23 [48–50]. This kind
of gene clustering pattern has been observed for defensin genes
in other species as well [51–54]. The HβD-3 gene contains two
exons located 13 kb upstream of HβD-2 gene. The first exon
includes the 5′ untranslated region of the gene that encodes a
domain of the preprotein. The second exon encodes the mature
peptide, which contains 6 cysteine residues that form three
intramolecular disulfide bonds. A genomics approach employ-
ing a computational search strategy for the discovery of β-
defensin genes (using Hidden Markov Models for the six-
cysteine conserved structural motifs) identified 28 new genes
clustered on several different chromosomes [20].
In vitro studies indicated that the expression of HβD-3
mRNA in cultured primary bronchial epithelial cells is inhibited
by dexamethasone, a corticosteroid, but not by mRNA levels of
HβD-1 and HβD-2 [55]. Corticosteroids are known to inhibit
the synthesis of many pro-inflammatory cytokines and cell
surface molecules [56]. The in vitro bactericidal activity of
HβD-3 has been found to be inhibited by saliva and serum
against S. mutans and A. actinomycetemcomitans but the
inhibition of the activity can be overcome with an increase in
the peptide concentration [57]. It has been shown that cysteine
proteases like cathepsins B, L, and S that are present and active
in CF bronchoalveolar lavage have the ability to degrade and
inactivate HβD-3. Hence, HβD-3 is susceptible to cathepsins
(e.g. host proteases) and therefore, cathepsins play an important
role in the regulation of HβD-3 activity. The over expression of
cathepsins may lead to degradation and thereby favor bacterial
infection [58]. It has been reported that antibacterial activities of
HβD-3 and other host-defense peptides are inhibited by a
31 kDa protein, streptococcal inhibitor of complement (SIC)
secreted predominately by M1 strains of group A streptococci
(GAS). Another protein that is distantly related to SIC also
inhibited the antibacterial activity of HβD-3, but to a lesser
extent compared to SIC, indicating a role for virulence factors of
bacteria that protect them from antibacterial action [59,60].
Hence, the identification of several defensin genes and their
homologs in diverse biological systems indicates either the
common need for these molecules throughout evolution or that
they have been tuned to a specific sequence by mutation,resulting in their common tertiary structure without a significant
sequence homology.
There are only a few studies on the isolation, cloning and
expression of HβD-3 but the chemical synthetic protocols are
well documented [3,16,23,25,61–66]. Further studies involving
a synthetic approach for the generation of HβD-3 or its
derivatives would help in exploring the involvement of this
molecule in unrecognized biological activities.
4. Structure of HβD-3
HβD-3 is a 45-residues, cationic peptide with an asymme-
trical distribution of charged residues, mostly clustered at the
carboxyl-terminal region. It has a low sequence similarity
among β-defensin class of peptides [16,20,23,25,42]. HβD-3
has been primarily isolated, characterized from psoriatic scales,
and classified as a member of the β-defensin family of
peptides [25,67]. The isolated and characterized human β-
defensins are defined by six-cysteine motif spacing C–X6–C–
X4–C–X9–C–X6–CC (where Xn indicates n non-cysteine
residues) and have the same cysteine connectivity as found in
bovine neutrophil beta-defensin-12 (BNBD-12), bovine tra-
cheal antimicrobial peptide (TAP), and bovine lingual
antimicrobial peptide (LAP) [68]. However, the spacings are
some what different in other defensins like HβD-4, HβD-27
and HβD-28. The sequence alignments and disulfide con-
nectivities of defensins are shown in Fig. 1, including the
recently synthesized and characterized HβD-27 and HβD-28
peptides that are found in chromosome 20 [66]. The three
disulfide bonds found in HβD differ from α-defensins with
respect to first and third Cys–Cys connectivities whereas the
disulfide connectivity between the second and fourth cysteine
residues is conserved among these two classes of peptides.
Despite the differences in disulfide connectivities, the tertiary
structure of these two classes of peptides is similar
[13,15,61,62,69].
Studies on the secondary structure of HβD-3 using circular
dichroism (CD) experiments in aqueous buffer, trifluoroethanol
(TFE) and sodium dodecyl sulfate (SDS) micelles have been
reported [16]. The results in aqueous medium showed
approximately 25% of residues in a β-sheet conformation and
<10% of the residues in an α-helical conformation. However, in
the presence of 50% TFE, the peptide undergoes a marked
conformational transition with an increase in the helicity of the
peptide to 25% while its β-sheet conformation is unchanged
(16). Similar structural transition was also observed in SDS
micelle. These studies attributed the increase in helical structure
of the peptide to the flexible N-terminus region of the peptide.
The solution nuclear magnetic resonance (NMR) spectro-
scopy studies in water at a low pH showed the formation of
three anti-parallel beta-sheets in the stabilization of the tertiary
structure and a short helical loop at the amino-terminal region of
the peptide [62]. The primary sequence and the regions
spanning the secondary structures are shown in Fig. 2A. The
assigned nuclear Overhouser effect (NOE) connectivities
indicate that the β3-sheet serves as a template for the β2 and
β1 sheets in the stabilization of the tertiary structure among the
Fig. 1. Amino acid sequence and cysteine connectivities in HβD's. (A) Primary sequences of human beta-defensins. A gap (marked by −) was introduced in all
peptides for the sequence alignment as the spacing between second and third cysteines is observed to be three residues as compared to the consensus of four residues in
HβD-1-3. (B) The consensus disulfide connectivities among beta-defensins.
Fig. 2. Structural aspects of HβD-3. (A) Primary sequence alignment and the secondary structural features spanning the peptide as observed by the NOE connectivity
[49]. (B) Cartoon model for the interaction among the three beta strands for the stabilization of monomers. The three β-strands (β1, β2, and β3) stack in an antiparallel
manner. (C) A tertiary structure of the monomer. The Glu and Lys residues on the β-2 sheet are shown. (D) Electrostatic surface plot. The basic regions are colored in
blue and the acidic regions are in red (49). (E) The interaction between the two β2 strands is stabilized by salt bridge formation involving residues Glu-28 and Lys-32 in
an antiparallel manner as shown by the dashed lines. (F) A three-dimensional view across two β2 strands in a dimer (62).
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the protein data bank (PDB) data file and electrostatic surface
plot of monomeric form is shown in Fig. 2C and D. The studies
involving native gel migration method, dynamic and static light
scattering, and NMR diffusion measurement of the radius of
hydration demonstrated that only HβD-3 has the ability to form
an amphipathic symmetrical dimer structure through the β2
strand, which exhibits increased positive surface charge upon
folding as compared to HβD-1 and HβD-2 (Fig. 2E and F). This
property of HβD-3 has been speculated to be responsible for
increased anti-S. aureus activity and salt insensitivity; therefore
this molecule has been possibly implicated in diseases like
cystic fibrosis where many of the host defense peptides are
inactivated due to increased salt concentration [22,70–72].
In an attempt to understand the role of dimerization in
antibacterial activity, an analog ftkHβD-3 was synthesized in
which the three residues, Lys26–Glu27–Glu28 involved in the
dimerization of HβD-3 were replaced by Phe–Thr–Lys, the
residues present in HβD-1 [16]. A synthetic hcβD-3 peptide
found in Hylobates concolor has also been studied [16]; the
amino acid residues at 2 (Leu), 3 (Met) and 17 (Trp) sites of this
peptide differ from that of HβD-3. These two analogs did not
undergo oligomerization as observed on sodium dodecyl
sulfate-polyacrylamide gel (SDS-PAGE) electrophoresis under
non-reducing and reducing conditions but their antibacterial
activity was comparable against the microorganisms tested.
Though the analogs ftkHβD-3 and hcβD-3 differ considerably
in the formation of higher ordered structures compared to native
HβD-3, their antibacterial activities in the presence of salt,
kinetics of killing and membrane permeabilization of Gram-
negative and Gram-positive bacteria did not distinguish the
native peptide from these two analogs. This observation
indicates that the ability to undergo dimerization is not an
essential requirement for the antibacterial activity towards S.
aureus and also for the antibacterial activity in the presence of
salt. However, the fact that Hβd-3 undergoes dimerization and/
or forms higher order structures imply that this molecule also
plays an important role in other biological functions where the
interaction of Hβd-3 with cells could be receptor mediated.
The crystal structure of human neutrophil peptide-3 (HNP-3)
revealed an amphiphilic dimeric beta-sheet assembly (15). This
structure has been suggested to be important in binding and
permeabilization of membranes in order to exhibit its
antibacterial activity [15]. Other members of the same family,
HNP-1 and HNP-2, also have been shown to undergo dime-
rization/oligomerization in solution or in unilamellar lipid vesi-
cles [73,74]. The solution NMR structure of bovine neutrophil
beta-defensin-12 (BNBD-12) showed a ‘defensin-like fold’
involving three β-strands identical to that of HNP-1–3, even
though BNBD-12 and HNP-1–3 have different disulfide
connectivities [75,76]. Several studies reported the structure
of human beta-defensins (HβD-1–3) using NMR and X-ray
crystallography approaches [13,77,78]. In the concentration
range of 0.5–2.4 mM HβD-2, the solution NMR and static light
scattering studies did not provide any evidence for the
oligomerization of the peptide [77]. On the other hand, the
formation of HBD-2 dimers was observed using dynamic lightscattering studies at concentrations above 6.9 mM [78]. HβD-2
has also been crystallized and in the crystalline state it was
found to be in a dimeric form [78]. Interestingly, the mode of
dimerization was found to enable the formation of an octameric
form of the protein [78]. The higher-order oligomeric structures
were found to be stable due to the burial of the hydrophobic
surface area and the uniform surface distribution of positively
charged residues. Thus, the structural and electrostatic proper-
ties of HβD-2 neither favor the insertion of the peptide or nor
the formation of pores in membranes. Thereby, the proposed
model suggests an electrostatic interaction of HβD-2 with the
polar lipid head group to disrupt the bacterial membrane
integrity for membrane permeabilization [78].
A crystal structure of HβD-1 revealed a dimeric form of the
peptide with a typical human ‘β-defensin-like fold’ (an N-
terminal α-helical segment and three antiparallel β-sheets),
however, unlike for HβD-2, no higher-order oligomeric forms
were found [13]. Also, the topology of HβD-1 dimers formed
between monomers in the asymmetric units is different from
that of HβD-2 suggesting a little support for the formation of
membrane-embedded pores unlike the dimeric forms of HβD-2
and HNP-3 [13]. Since the human β-defensins share a common
‘β-defensin-like fold’, the activities of these peptides are
believed to be dictated by their quaternary structures. It is
speculated that Hβd-3 functions via carpet-type mechanism of
membrane-disruption as it is highly cationic and has an ability
to form dimerization and/or oligomerization, which is in
agreement with a recent study [63].
Although the molecular size of chemokines, such as CCL20/
MIP-3á, are larger than β-defensins, their tertiary structure,
cationicity and antibacterial activity are similar to that of β-
defensins. On the other hand, it is surprising to note that β-
defensins interact with chemokine receptors like, CCR6
[79,80]. The peptide derived from interleukin-8 (IL-8) has
been shown to exhibit antibacterial activity but lacks the
proinflammatory effect. This finding suggests that IL-8 contains
structural elements that are capable of interacting with
membranes, even though the full-length IL-8 do not possess
antibacterial activity [81]. A recent study on the structural
congruence among membrane-active host defense peptides/
proteins highlights the importance of the conserved structural
motif called γ-motif in diverse cysteine-containing molecules,
like chemokines, antibacterial peptides, and toxins [82]. Thus,
the function of such effector molecules is governed by specific
configurational modules associated with a common γ-core
motif that have evolved by parallel and divergent process [82].
5. Biological activities of HβD-3
Though HβD-3, unlike other defensin peptides, has been
primarily shown to possess a broad spectrum of antibacterial
activity against many pathogens and drug resistant microbes
[25,61,63,83,84], a recent study suggests that HβD-3 is also
involved in several other biological functions such as chemo-
attraction, thereby connecting innate and adaptive immunity
[63]. Antibacterial and biochemical properties of the recombi-
nant and chemically synthesized HβD-3 are indistinguishable
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reports in the recent past on the validation of antibacterial
activity of this molecule towards array of bacteria including the
resistant strains using different experimental protocols. The
kinetics of bactericidal activity and bactericidal activity in
presence of human serum has been evaluated for peptide, HβD-
3 against multidrug-resistant clinical isolates of common noso-
comial pathogens, such as Staphylococcus aureus, Enterococ-
cus faecium, and Pseudomonas aeruginosa, and clinical
isolates of emergent pathogens, such as Stenotrophomonas
maltophilia and Acinetobacter baumannii. The concentration
required for the bactericidal effect monitored after 1.5 h of
incubation found to be in the range 4–8 μg/ml but the activity
lowered in presence of 20% heat inactivated serum [85]. The
Table 2 summarizes a few of the antibacterial activity of this
peptide for antibacterial towards different microorganisms. A
majority of the experiments are done for the determination of
minimum inhibitory concentration (MIC) and lethal concentra-
tion (LC) and these assays have merits on their own. However,
it is worth mentioning two methods for the evaluation of
antibacterial activity of defensin peptides. The determination of
virtual lethal doses (VLD) is more informative as the kinetics of
growth/killing can be monitored directly [86] The second
method, a quantitative flow cytometric assay using a membrane
sensitive dye is developed to monitor antibacterial activity of
HβD-3 against different bacterial species [87].
Unlike several cationic peptides, HβD-3 did not exhibit
cytotoxic activity against eukaryotic cells. It exhibited a very
low or <0.5% hemolytic activity towards human erythrocytes
when a high amount of peptide (up to 500 μg/ml) was used at
physiological salt concentrations. A higher hemolytic activity
was observed in the presence of 10 mM sodium phosphate
buffer containing 0.34 M sucrose [25]. Similar studies on
human erythrocytes showed <10% hemolytic activity at
100 μg/ml and ∼30% at 500 μg/ml [88]. When the cytotoxic
activity was measured against monocytic human THP-1 cells,
peptide HβD-3 had no effect on the viability at a concentration
of 10 μg/ml but the viability of these cells was reduced
significantly when incubated with a peptide concentration ofTable 2
Antimicrobial activity of HβD-3 against different microbes
Microorganism MIC/LC90 (μg/ml) Reference
E. coli ATCC 11303 6.0 [25]
E. coli ATCC 25922 6.0 [61]
E. coli D5α 3.13 [83]
S. aureus ATCC 6538 12.0 [25]
S. aureus ATCC 29213 12.0 [61]
S. aureus ATCC 6538 and 150 mM salt 12.0 [25]
S. aureus multi drug resistant clinical isolate ~25.0 [25]
E. faecium vancomycin resistant 12.0 [25]
P. aeruginosa ATCC 27853 13.0 [25]
S. pyogenes ATCC 12344 12.0 [25]
C. albicans clinical isolate 6.0 [25]
C. albicans 99788, amphotericin B resistant 18.0 [61]
F. nucleatum (ATCC 25586) >100.0 [83]
P. gingivalis (ATCC 33277) 12.5 [83]
MIC=minimum inhibitory concentration LC90= lethal concentration required
for 90% mortality.50 μg/ml which is about 4–5 fold excess than required for the
antibacterial activity [88].
A majority of antibacterial peptides are known to act by
permeabilization of the bacterial membrane via different types
of mechanisms that include membrane depolarization and
creation of physical holes in membrane [89–99]. Also,
membrane permeabilization studies indicate that membrane
composition modulates the activity [98,100–102]. Several
models have been proposed for membrane interactions that
include carpet, barrel stave, or torroidal pore formation by
various biophysical studies [103–112]. These studies have led
to the design of peptides exhibiting selective activity [101,113–
116]. Apart from membrane permeabilization, it is also known
that antibacterial peptides activate the induction of hydrolases,
which degrade the cell wall or interfere with the distribution of
lipids in the two leaflets of the bilayer. This results in non-
maintenance of the membrane integrity and function [117,118].
These molecules are also found to translocate across the
membrane and interfere with critical cellular functions that lead
to cell death [119].
Studies using transmission electron microscopy demon-
strated that HβD-3 has the ability to induce morphological
changes, like perforation of the peripheral cell wall and
explosion-like liberation of the plasma membrane within
about 30 min of interaction with the S. aureus membrane
suggesting that the plasma membrane is the site of action [25].
Similar studies on C. jejuni, bacteria known to cause diarrhea in
human, showed thinning of cell wall with the formation of
membrane-enclosed blebs that lead to subsequent loss of
cytoplasmic contents when incubated with HβD-3. This
observation also suggests that the disruption of cell wall
integrity is the cause for the bactericidal effect [120]. The
membrane-permeabilization kinetics studies measured as β-
galactosidase enzyme activity towards E. coli ML-35 pYC and
S. aureus 710A strains indicated that the peptide is capable of
initiating permeabilization of the cytoplasmic membrane of E.
coli within 20–30 min whereas the permeabilization of the
cytoplasmic membrane is much slower for the Gram-positive
microorganism [16]. These results complemented with the
studies by the same group on the kinetics of bacterial killing of
both Gram-negative and Gram-positive microorganism. HβD-3
has been shown to kill E. coli cells efficiently in less than
30 min while similar effect was observed after 120 min against
Gram-positive S. aureus. These studies imply the possible roles
of each membrane component to act as a barrier towards this
peptide as the chemical composition of these bacterial
membranes are different. HβD-3 also has been shown to have
the ability to form non-selective ion-channels in the oocyte
membranes of Xenopus laevis [23].
Several of the cationic antibacterial peptides have been found
to possess anti-endotoxin properties by binding to lipopoly-
saccharide (LPS) and lipoteichoic acid (LTA) and thereby
prevent the sepsis or septic shock that is associated with the
presence of pathogenic Gram-negative and Gram-positive
bacteria [121–128]. Similarly, human β-defensin HβD-2,
belonging to a class of cationic antimicrobial peptides, exhibited
the ability to block the LPS interaction and is correlated with
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responsible for inflammation [127]. Due to polycationic nature
of HβD-3 (+11 in monomeric form), it can effectively interact
with the anionic charges on the LPS molecule and neutralize the
endotoxic activity. Recent studies using atomic force micro-
scope (AFM), electrical measurements on interaction of HβD-3
with LPS monolayers suggest this peptide has the potential to
intercalate and also form lesions [129]. Their results correlated
with the antibacterial activity and thereby it is hypothesized that
lipid–peptide specific interactions are involved in biological
activity of HβD-3. Thus, HβD-3 has the ability to bind,
neutralize LPS and thereby exhibit anti-endotoxin property like
HβD-2. However, the exact mechanism of action for the
membrane interaction is yet to be carried out in detail. Wu et al.,
have suggested a carpet model for the mode of action and
destruction of the membrane that is aided by a high number of
positive charges in the amphiphilic structure [63].
Apart from the antibacterial activity, HβD-3 has been shown
to possess immunomodulatory properties such as chemoattrac-
tion of T-lymphocytes and immature dendritic cells, thus
playing an important role in adaptive immunity. The optimal
concentration for the migration of monocytes and CCR6-
transfected human embryonic kidney (HEK) 293 cells was
found to be 100 ng/ml and 10 ng/ml respectively as assayed by
microchemotaxis chamber technique method [130]. HβD-3 is
known to interact with chemokine receptor CCR6 by direct
binding [63]. This molecule has been also reported to induce
secretion of IL-18, a proinflammatory cytokine in human
keratinocytes [131]. The ability of HβD-3 to kill bacteria and
activate immune cells indicates that these molecules are
involved in innate and adaptive immunity like other defensin
molecules [132–134]. Additional biological activities include:
HβD-3 has been shown to exhibit the inhibition of HIV-1
replication in vitro similar to peptide HβD-2, induction of tissue
remodeling proteins such as matrix metalloproteinases (MMPs)
and reduction of MMP's inhibitors (TIMP-1/-2) in human
cartilage [45,135,136]. These biological activities demonstrate
multifunctional roles of HBD-3.
6. Correlation of structure and function of HβD-3 analogs
In order to exploit the structure–function relationships of
HβD-3 and to understand the rationale for the design of potent
active molecules, several peptide analogs that differ in disulfide
connectivities, length, cationic charges, hydrophobicity have
been generated [61,63,88]. The sequences and the biological
activities of HβD-3 (peptide-1) and its analogs (peptides 2–28)
are summarized in Table 3. It should be noted that three
independent measurements on antibacterial assay included in
Table 3 cannot be compared directly. Moreover, the antibacter-
ial activity also depends on the type of experiment, nature of
medium, ionic strength of the medium, and the type of species
used in assay conditions.
Important results from the structure–function correlation
studies are summarized below. A synthetic peptide wherein the
disulfide linkages are misfolded (or differing in the S–S
connectivity) showed comparable antibacterial activity to thenative peptide towards E. coli [63]. For example, peptides 2–6
that differ in disulfide connectivities among themselves as well
as with the native HβD-3 peptide (peptide-1) (see Table 3) but
exhibit similar antibacterial activity. Analogs devoid of 5
(peptides 8, 9, 10), 7 (peptide-14) and 9 (peptide-15) N-terminal
amino acids but containing all the three native or non-native
disulfide connectivities also exhibited the same antibacterial
activity as that of HβD-3 indicating the misfolding of three
disulfides and deletion of 9 N-terminus residues did not affect
the antibacterial activity. However, the linear analogs in which
all cysteines were substituted by α-aminobutyric acid (peptide-7
in Table 3) and peptide-11 with a deletion of five N-terminal
residues in which Cyswere carboxymethylated (peptide-11) also
exhibited antibacterial activity. These results suggest that the
correct location of Cys–Cys connectivities and the formation of
a tertiary structure are not essential for the exhibition of
antibacterial activity. This observation is again supported by 5
N-terminal deleted analogs (peptides-2 and peptide-13 that span
all the three disulfide region in HβD-3) where all Cys residues
replaced by Ala and Trp did not affect the antibacterial activity
towards Gram-negative and Gram-positive bacteria.
The studies on shorter peptides containing one or two
disulfide bridges did not clearly establish the role of Cys–Cys
connectivity in the native molecule. Peptide-16, that is devoid
of 18 N-terminal residues with two non-native disulfide
connectivities, and peptide-25, containing 17 residues with
single non-native disulfide connectivity, showed a drastic drop
in antibacterial activity. As these analogs (having single and two
disulfides) vary in length, cationic charges, hydrophobicity and
span different regions of the HβD-3, it is difficult to conclude
which of the property is important in modulating the
antibacterial activity.
Interestingly, peptides as short as 9 amino acids (peptide-22)
corresponding to the C-terminal region exhibited antibacterial
activity towards E. coli. Addition of cationic charged residues
enhanced the activity as observed in peptides 20 and 21.
However, further increase in length (peptide-19) lowered the
antibacterial activity as compared to its shorter analog, peptide-
20 indicating the importance of cationic charges as observed in
several cationic peptides. Two short analogs peptides (23 and
24), corresponding to N-terminal region were also active
towards E. coli. However, all these shorter analogs exhibited
lower activity towards Gram-positive bacteria.
The effect of hydrophobicity towards antibacterial activity
was studied by the generation of peptides wherein Cys have
been replaced by Trp. Peptide-13, that lacks 5 N-terminal
residues and all Cys replaced by Trp, showed lower activity
compared to their three Cys–Cys bridged analogs, peptides 8, 9
and 10 towards Gram-positive and Gram-negative bacteria.
Peptide-12, that lacks 5 N-terminal residues and all Cys
replaced with Ala, had similar activity as the Trp replaced
analog (peptide-13). However, similar replacement in shorter
analogs in peptides 18 and 27 significantly increased the
antibacterial activity as compared to their disulfide analogs,
peptides 16 and 25 containing two and one Cys–Cys
connectivities and corresponding to different regions of the
native peptide 1, HβD-3. Even the Cys replacements by residue
Table 3
Overview of the primary sequence alignment and biological activities of HβD-3 and its analogs studied
X–Y numbers indicate the Cys connectivity; for example, 1–5 indicates first Cys from the amino terminal connected to the fifth Cys. a=α-aminobutyric acid, Cam=carboxamidomethyl, bold letters indicate the
change of amino acid from the native peptide. Antibacterial activity against (A) E. coli and (B) S. aureus either at *=LC50 or #=LC90 μg/ml. LC50 or LC90 is the concentration of protein at which 50 or 90% of the
viable cells are killed. $=minimum inhibitory concentration (MIC) in μg/ml measured in ¼ MHB culture medium. &=MIC in μM in 5% tryptic soya broth while the MICs of native peptide towards each of these
organisms were 1 μM. Chemotactic activity against (C) monocytes and (D) HEK in ng/ml. @=not active at >10,000 ng/ml.
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compared to their disulfide bridged ones (peptides 16 and 25).
Hence, the increase in hydrophobicity enhanced the antibacter-
ial potency in shorter analogs containing 17 and 27 residues
than to its longer analog (peptide-13).
Primary structure–function analysis on these analogs
suggests that the C-terminal segment with higher cationic
charges is important for antibacterial activity towards Gram-
negative bacteria while the native peptide exhibited optimal
antibacterial activity towards both Gram-negative and Gram-
positive bacteria. This finding possibly, indicates the impor-
tance of N-terminus and hydrophobic residues in modulating
antibacterial activity of HβD-3 against Gram-positive bacteria,
S. aureus and hence, useful in the design of peptides that exhibit
selective inhibition of growth of either Gram-negative or Gram-
positive bacteria.
Though the role of reduced form of disulfide linkages in
native peptide was not established, Campopiano et al., observed
that the native folding is necessary for higher antibacterial
activity in defensin-related peptide Defr1 [137]. Reduced
peptides (i.e., without S–S bonds) were less active compared
to oxidized peptides. Reduced and oxidized forms showed
different mobility patterns on non-denaturing 16% tricine gel,
indicating the ability to form higher ordered structures and their
possible role in folding and biological activity. We observed that
the folded form of HβD-3 is protected to a greater extent from
in vitro degradation by serine–threonine proteases like, trypsin
as compared to the linear one which is reduced and alkylated. It
has been supported by the observation that the peptides 8, 9, and
10 that have three disulfide folding exhibited higher anti-S.
aureus activity as compared to its linear counterparts in peptides
11, 12 and 13 (Table 3). This implies the importance of
disulfides in the formation of tertiary structures to overcome the
degradation by proteases secreted by several bacteria.
The analogs were also tested for the ability to interact with
immune cell lines. The analogs having the non-native three
disulfide connectivities also exhibited chemotaxis at different
concentrations. On the other hand, the replacement of all Cys by
α-aminobutyric acid completely abolishes the chemotactic
activity of HβD-3 [63]. This observation clearly suggests that
three disulfide bond (either native or non-native) induced
tertiary structure are important for the binding and activation of
receptors for chemotaxis.
There is only one report on cytotoxic activity of HβD-3
analogs towards human erythrocytes and monocytic THP-1
cells [88]. Peptides with 5 N-terminal residues with three
disulfide connectivities (peptides 8, 9 and 10) and Cys
substitution by Ala (peptide-12) or Trp (peptide-13) were
assessed for their cytotoxic activity. The N-terminal deleted
peptides with native or non-native Cys–Cys connectivities
showed higher viability as compared to its full length HβD-3
towards the THP-1 cell line. The alanine substitution did not
change the viability while the Trp substitution leads to show a
higher potency in reducing the viability of the same cells at
concentrations 100 μg/ml. A similar activity profile was also
observed in human erythrocytes. Peptides with N-terminal
deleted analogs with three disulfide connectivities were lessactive compare to the native peptide-1. Substitution of Ala did
not change the lytic activity whereas Trp substitution enhanced
the hemolysis when compared to the peptides of same length.
The structural determination by CD in water of HβD-3
derivatives (peptides 8, 9, 10, 12, 13, 16 and 25), exhibited
similar spectrum as native peptide 1 indicating disulfide
bridges, substitution of Cys by Ala or Trp residues has no
effect towards formation of secondary structures and biological
activities like antibacterial and hemolytic activities [88]. It is
important to mention that the aqueous structure do not clearly
reflect the biological activity of peptides as majority of the
membrane active peptides have random conformation and
transform to ordered secondary structures in the presence of
lipid media/ membrane mimicking environment.
The structure–function correlation studies indicate that the
antibacterial activity of HβD-3 depends on cationic charges
while an increase in the hydrophobicity of designed analogs
enhanced the activity towards Gram-positive and Gram-
negative bacteria and induced cytotoxic activity. Cationic
Hβd-3 derivatives, as short as 9–14 residues in length, from
the C-terminal region can exhibit potent anti-E. coli activity.
The studies on HβD-3 and its full length analogs suggest that
the structures induced by the disulfide bonds are dispensable for
both antibacterial and chemotaxis activities, whereas the
absence of disulfide bonds leads to antibacterial activity only.
This finding gives a flexibility in designing potent antimicro-
bials (either linear or cyclized analogs) as non-chemotactic
therapeutic agents. The development of such molecules is a
promise for non-immunogenic antibiotics to humans in
combating pathogens. These findings are also in agreement
with a recent study that investigated the role of Cys–Cys
connectivities in tachyplesin [138].
Thus, the structure–function analysis of defensin peptides
indicates that their consensus cysteine sequence, connectivity
and tertiary structures are optimized towards modulation of
biological functions other than antibacterial activity. HβD-3,
being also an inducible peptide expressed upon challenge, is
important in fighting the bacterial invasion and it appears that its
constitutive expression is important in controlling other
biological functions. The concentrations required for the
antibacterial activity is about 100–1000 fold excess compared
to the immunomodulatory activity shown by this peptide. To
consolidate, this peptide is involved in several biological
functions like, antimicrobial activity against an array of
microorganisms, interaction with immune cells, inhibition of
HIV replication, anti-endotoxin activity, interactions with
membrane components, induction of tissue modeling proteins
and so on. Thus, involvement of HβD-3 in diverse activities is
recognized as possessing multiple functions that belongs to a
class of β-defensin peptides.
7. Future scope
Recently published papers report on the details of mamma-
lian and human defensins, evolution of β-defensins, and the
antibiotic activity of HβD-3 [17,92]. Another recent review
article, published during the preparation of our article, presents
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and multi-functional peptides of the immune system [4].
Therefore, this article focused on HβD-3 emphasizing on the
importance of its structure and function.
Though constitutive or inducible production of antibacterial
peptides is a host defense strategy used by various species,
pathogens also have evolved with resistance mechanisms to
host defense. Several resistance mechanisms operate in the
pathogen to resist the killing effect by the host antibacterial
peptide. Presently it is not well understood whether a lower
expression or a deficiency in expression of these host defense
peptides would lead to a successful survival of the pathogen and
a progress of disease. However, in vitro studies have indicated
that microbes develop resistance towards these host defense
molecules when pretreated with sublethal concentrations [83].
Our preliminary work in collaboration with Dr. Shelburne's
research group using 2D-HPLC indicated a change in the total
protein expression profile of an anaerobe, P. gingivalis, as
compared to the untreated one (unpublished data). This
intriguing observation would help us to understand the possible
roles of new proteins towards the development of resistance or
the survival mechanisms that the microbes undergo against the
host defense molecules. This finding opens a new area of
research for the development of drugs towards combating the
microbes that are resistant towards host defense molecules.
Research in our laboratory is also aimed at understanding
the mechanism of action of diverse biological functions of
HβD-3 and the design of shorter peptide analogs of HβD-3 for
biophysical studies. Though, the involvement of HβD-3 in
innate and adaptive immunity is well established, it is not clear
which of the parameters (e.g. primary structure, charge,
hydrophobicity, tertiary or quaternary structure) in the native
molecule are important for its biological function. Our pre-
liminary investigations into the structure–function relation-
ships via biophysical studies involving cyclic and linear
analogs of 20–25 residues, GRCAVLSWLPKEEQIGKCSTR
and LSCLPKEEQIGKWSTRGRKSCRRKK spanning two
different regions of HβD-3 indicates that these analogs have the
ability to interact selectively with anionic liposomes and exhibit
moderate inhibition of growth in Gram-negative and Gram-
positive bacteria with MICs values in the range 25–150 μg/ml.
These molecules did not lyse sheep erythrocytes and were non-
toxic to cultured human monocytic THP-1 cells to a concentration
of 150–200 μg/ml indicating their non-toxic property towards
mammalian cells. It is unlikely that such analogs are immunogenic,
as they are part of the native peptide and are not expected to
interfere in immunomodulatory function in humans, as they do not
form tertiary structures like the native peptide involving three
disulfides. The Biophysical studies involving the outer-membrane
components are also under investigation to understand the
neutralizing ability of these peptides towards endotoxic compo-
nents like, LPS andLTAof bothGram-negative andGram-positive
bacteria and thereby control the LPS induced inflammation. Our
studies in this direction would lead towards the design of potent
antibacterial, non-immunogenic short peptides that might have
therapeutic importance. We believe that HβD-3 is presently
underexplored and there is a tremendous amount of research onthis exciting molecule needs to be carried out to further
understand its multiple functions that play a vital role in the
maintenance of human health.
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